Cointime

BioSight

company

About

Innovative Cancer Targeted Pro-Drugs.

  • 1 - 10

Highlights

Total Funding Amount
$27M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Series C
Last Funding Money Raised
$27M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2000
Number Of Employee
1 - 10
Operating Status
Active

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$27M
BioSight has raised a total of $27M in funding over 2 rounds. Their latest funding was raised on Dec 2, 2020 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 2, 2020 Series C $27M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
BioSight is funded by 2 investors. Phoenix Insurance Company and Biotel are the most recent investors.
Investor Name Lead Investor Funding Round
Phoenix Insurance Company — Series C
Biotel — Series C
Cointime
Содержание
компания